Save your research. Keep your calculations. See what changed.

• CorrectionBPC-157· referencesOct 24, 2026New

  Removed a ClinicalTrials.gov record (NCT07437547) that its sponsor describes as an example, not a real study.

  Previous vs current wordingSource: BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547)
• CorrectionGHK-Cu· referencesOct 24, 2026New

  Removed a ClinicalTrials.gov record (NCT07437586) that its sponsor describes as an example, not a real study.

  Previous vs current wordingSource: Topical GHK-Cu Gel for Acute Skin Wound Healing (NCT07437586)
• New sectionRetatrutide· Schedules by time periodOct 23, 2026New

  Added week-by-week schedules from registered trials (5 groups, 21 arms).

  Source: A Study of LY3437943 in Participants Who Have Obesity or Are Overweight (registry record and posted study protocol J1I-MC-GZBF)
• New sectionCagrilintide· Schedules by time periodOct 23, 2026New

  Added week-by-week schedules from registered trials (1 group, 5 arms).

  Source: Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity (registry results: participant flow group descriptions)
• New sectionSemaglutide· Schedules by time periodOct 23, 2026New

  Added week-by-week schedules from the FDA label (4 groups, 11 arms).

  Source: OZEMPIC (semaglutide) injection, for subcutaneous use - prescribing information
• CorrectionCagrilintide· Quick reference: half-lifeOct 23, 2026New

  Re-cited the half-life to the phase 1b study that measured it, and noted it was measured alongside semaglutide.

  Previous vs current wordingSource: PubMed 34798060

• 
  BPC-1571 new

  Not approved — research use only · Evidence Grade C

  FollowDosingCalculator
• 
  Retatrutide2 new

  Investigational · Evidence Grade A

  FollowingDosingCalculator
• 
  Semaglutide2 new

  FDA-approved · Evidence Grade A

  FollowingDosingCalculator
• 
  GHK-Cu1 new

  Not approved — research use only · Evidence Grade B

  FollowDosingCalculator

• 5 mg vial in 2 mL

  Reconstitution concentration · saved Oct 22, 2026

  Vial contents (mg): 5 · Diluent added (mL): 2
  Concentration: 2.5 mg/mL

  OpenExport
• Working stock for assay plate

  Dilution (C1V1 = C2V2) · saved Oct 20, 2026

  Stock concentration: 2.5 mg/mL · Target concentration: 0.25 mg/mL · Final volume: 1 mL
  Stock to add: 0.1 mL

  OpenExport

Your own numbers, computed by laboratory arithmetic. Not doses and not recommendations.

• Retatrutide vs TirzepatideOct 21, 2026